Search for a trial | Research with human participants

1 results

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants with Relapsed or Refractory Multiple Myeloma

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2023-503679-12-00 check the CTIS register for the current data. Part 1 (Dose Escalation) - to identify the recommended Phase 2 dose(s) and schedule(s) to be safe for JNJ-79635322. Part 2 (Dose…